Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Patient Derived Chicken Egg Tumor Model (PDcE Model): Current Status and Critical Issues.

Komatsu A, Matsumoto K, Saito T, Muto M, Tamanoi F.

Cells. 2019 May 10;8(5). pii: E440. doi: 10.3390/cells8050440. Review.

2.

Preface.

Tamanoi F.

Enzymes. 2018;44:xi. doi: 10.1016/S1874-6047(18)30035-0. No abstract available.

PMID:
30360817
3.

Tumor Targeting and Tumor Growth Inhibition Capability of Mesoporous Silica Nanoparticles in Mouse Models.

Le Hoang Doan T, Mai NXD, Matsumoto K, Tamanoi F.

Enzymes. 2018;44:61-82. doi: 10.1016/bs.enz.2018.09.002. Epub 2018 Oct 12.

PMID:
30360815
4.

Anticancer Drug Delivery Capability of Biodegradable PMO in the Chicken Egg Tumor Model.

Matsumoto K, Le Hoang Doan T, Mai NXD, Nakai K, Komatsu A, Tamanoi F.

Enzymes. 2018;44:103-116. doi: 10.1016/bs.enz.2018.09.003. Epub 2018 Oct 12.

PMID:
30360810
5.

Preface.

Tamanoi F.

Enzymes. 2018;43:xi. doi: 10.1016/S1874-6047(18)30025-8. No abstract available.

PMID:
30244810
6.

Overview of Studies Regarding Mesoporous Silica Nanomaterials and Their Biomedical Application.

Vallet-Regi M, Tamanoi F.

Enzymes. 2018;43:1-10. doi: 10.1016/bs.enz.2018.07.001. Epub 2018 Sep 10.

PMID:
30244802
7.

Chick chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer.

Vu BT, Shahin SA, Croissant J, Fatieiev Y, Matsumoto K, Le-Hoang Doan T, Yik T, Simargi S, Conteras A, Ratliff L, Jimenez CM, Raehm L, Khashab N, Durand JO, Glackin C, Tamanoi F.

Sci Rep. 2018 Jun 4;8(1):8524. doi: 10.1038/s41598-018-25573-8.

8.

Miniaturization of thiol-organosilica nanoparticles induced by an anionic surfactant.

Doura T, Tamanoi F, Nakamura M.

J Colloid Interface Sci. 2018 Sep 15;526:51-62. doi: 10.1016/j.jcis.2018.04.090. Epub 2018 Apr 25.

PMID:
29715615
9.

Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer.

Shahin SA, Wang R, Simargi SI, Contreras A, Parra Echavarria L, Qu L, Wen W, Dellinger T, Unternaehrer J, Tamanoi F, Zink JI, Glackin CA.

Nanomedicine. 2018 Jun;14(4):1381-1394. doi: 10.1016/j.nano.2018.04.008. Epub 2018 Apr 14.

10.

Isolation and characterization of the primary epithelial breast cancer cells and the adjacent normal epithelial cells from Iranian women's breast cancer tumors.

Faridi N, Bathaie SZ, Abroun S, Farzaneh P, Karbasian H, Tamanoi F, Mohagheghi MA.

Cytotechnology. 2018 Apr;70(2):625-639. doi: 10.1007/s10616-017-0159-3. Epub 2018 Jan 29.

11.

An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation.

Heard JJ, Phung I, Potes MI, Tamanoi F.

BMC Cancer. 2018 Jan 10;18(1):69. doi: 10.1186/s12885-017-3938-5.

12.

Preface.

Hu TY, Tamanoi F.

Enzymes. 2017;42:xi. doi: 10.1016/S1874-6047(17)30034-3. No abstract available.

PMID:
29054273
13.

Exploiting Enzyme Alterations in Cancer for Drug Activation, Drug Delivery, and Nanotherapy.

Hayashi JY, Tamanoi F.

Enzymes. 2017;42:153-172. doi: 10.1016/bs.enz.2017.08.005. Epub 2017 Oct 10. Review.

PMID:
29054269
14.

A novel inhibitor of farnesyltransferase with a zinc site recognition moiety and a farnesyl group.

Tanaka A, Radwan MO, Hamasaki A, Ejima A, Obata E, Koga R, Tateishi H, Okamoto Y, Fujita M, Nakao M, Umezawa K, Tamanoi F, Otsuka M.

Bioorg Med Chem Lett. 2017 Aug 15;27(16):3862-3866. doi: 10.1016/j.bmcl.2017.06.047. Epub 2017 Jun 20.

PMID:
28666734
15.

Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models.

Roberts CM, Shahin SA, Wen W, Finlay JB, Dong J, Wang R, Dellinger TH, Zink JI, Tamanoi F, Glackin CA.

Nanomedicine. 2017 Apr;13(3):965-976. doi: 10.1016/j.nano.2016.11.010. Epub 2016 Nov 25.

PMID:
27890656
16.

Preface.

Lin C, Luan S, Tamanoi F.

Enzymes. 2016;40:ix-x. doi: 10.1016/S1874-6047(16)30035-X. No abstract available.

PMID:
27776784
17.

Biodegradable Oxamide-Phenylene-Based Mesoporous Organosilica Nanoparticles with Unprecedented Drug Payloads for Delivery in Cells.

Croissant JG, Fatieiev Y, Julfakyan K, Lu J, Emwas AH, Anjum DH, Omar H, Tamanoi F, Zink JI, Khashab NM.

Chemistry. 2016 Oct 10;22(42):14806-14811. doi: 10.1002/chem.201601714. Epub 2016 Jun 30.

PMID:
27258139
18.

Periodic Mesoporous Organosilica Nanoparticles with Controlled Morphologies and High Drug/Dye Loadings for Multicargo Delivery in Cancer Cells.

Croissant JG, Fatieiev Y, Omar H, Anjum DH, Gurinov A, Lu J, Tamanoi F, Zink JI, Khashab NM.

Chemistry. 2016 Jul 4;22(28):9607-15. doi: 10.1002/chem.201600587. Epub 2016 Jun 1.

PMID:
27245497
19.

Preface.

Kaguni LS, Oliveira MT, Tamanoi F.

Enzymes. 2016;39:xi. doi: 10.1016/S1874-6047(16)30017-8. No abstract available.

20.

Protein-gold clusters-capped mesoporous silica nanoparticles for high drug loading, autonomous gemcitabine/doxorubicin co-delivery, and in-vivo tumor imaging.

Croissant JG, Zhang D, Alsaiari S, Lu J, Deng L, Tamanoi F, AlMalik AM, Zink JI, Khashab NM.

J Control Release. 2016 May 10;229:183-191. doi: 10.1016/j.jconrel.2016.03.030. Epub 2016 Mar 23.

PMID:
27016140
21.

Mevalonate Pathway and Human Cancers.

Bathaie SZ, Ashrafi M, Azizian M, Tamanoi F.

Curr Mol Pharmacol. 2017;10(2):77-85. doi: 10.2174/1874467209666160112123205. Review.

PMID:
26758953
22.

Preface.

Inoue K, Stafforini D, Tamanoi F.

Enzymes. 2015;38:xi. doi: 10.1016/S1874-6047(15)00040-2. No abstract available.

PMID:
26612653
23.

Development of mesoporous silica-based nanoparticles with controlled release capability for cancer therapy.

Mekaru H, Lu J, Tamanoi F.

Adv Drug Deliv Rev. 2015 Dec 1;95:40-9. doi: 10.1016/j.addr.2015.09.009. Epub 2015 Oct 3. Review.

24.

Nanoformulation of Geranylgeranyltransferase-I Inhibitors for Cancer Therapy: Liposomal Encapsulation and pH-Dependent Delivery to Cancer Cells.

Lu J, Yoshimura K, Goto K, Lee C, Hamura K, Kwon O, Tamanoi F.

PLoS One. 2015 Sep 9;10(9):e0137595. doi: 10.1371/journal.pone.0137595. eCollection 2015.

25.

Preface.

Bathaie SZ, Tamanoi F.

Enzymes. 2015;37:xiii. doi: 10.1016/S1874-6047(15)00017-7. No abstract available.

PMID:
26298462
26.

How Phytochemicals Prevent Chemical Carcinogens and/or Suppress Tumor Growth?

Bathaie SZ, Faridi N, Nasimian A, Heidarzadeh H, Tamanoi F.

Enzymes. 2015;37:1-42. doi: 10.1016/bs.enz.2015.06.003. Epub 2015 Jul 29.

PMID:
26298454
27.

Significance of filamin A in mTORC2 function in glioblastoma.

Chantaravisoot N, Wongkongkathep P, Loo JA, Mischel PS, Tamanoi F.

Mol Cancer. 2015 Jul 2;14:127. doi: 10.1186/s12943-015-0396-z.

28.

Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden.

Finlay J, Roberts CM, Dong J, Zink JI, Tamanoi F, Glackin CA.

Nanomedicine. 2015 Oct;11(7):1657-66. doi: 10.1016/j.nano.2015.05.011. Epub 2015 Jun 24.

29.

Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis.

Mortazavi F, Lu J, Phan R, Lewis M, Trinidad K, Aljilani A, Pezeshkpour G, Tamanoi F.

BMC Cancer. 2015 May 9;15:381. doi: 10.1186/s12885-015-1360-4.

30.

Rheb protein binds CAD (carbamoyl-phosphate synthetase 2, aspartate transcarbamoylase, and dihydroorotase) protein in a GTP- and effector domain-dependent manner and influences its cellular localization and carbamoyl-phosphate synthetase (CPSase) activity.

Sato T, Akasu H, Shimono W, Matsu C, Fujiwara Y, Shibagaki Y, Heard JJ, Tamanoi F, Hattori S.

J Biol Chem. 2015 Jan 9;290(2):1096-105. doi: 10.1074/jbc.M114.592402. Epub 2014 Nov 24.

31.

Functional nanovalves on protein-coated nanoparticles for in vitro and in vivo controlled drug delivery.

Hwang AA, Lu J, Tamanoi F, Zink JI.

Small. 2015 Jan 21;11(3):319-328. doi: 10.1002/smll.201400765. Epub 2014 Sep 5.

32.

Hybrid mesoporous silica nanoparticles with pH-operated and complementary H-bonding caps as an autonomous drug-delivery system.

Théron C, Gallud A, Carcel C, Gary-Bobo M, Maynadier M, Garcia M, Lu J, Tamanoi F, Zink JI, Wong Chi Man M.

Chemistry. 2014 Jul 21;20(30):9372-80. doi: 10.1002/chem.201402864. Epub 2014 Jul 1.

PMID:
24986399
33.
34.

Recent progress in the study of the Rheb family GTPases.

Heard JJ, Fong V, Bathaie SZ, Tamanoi F.

Cell Signal. 2014 Sep;26(9):1950-7. doi: 10.1016/j.cellsig.2014.05.011. Epub 2014 May 24. Review.

35.

[Recent developments in targeted therapy for cancers and drug discovery].

Tamanoi F.

Nihon Yakurigaku Zasshi. 2014 May;143(5):236-42. Review. Japanese. No abstract available.

PMID:
24813794
36.

Two-photon-triggered drug delivery via fluorescent nanovalves.

Croissant J, Chaix A, Mongin O, Wang M, Clément S, Raehm L, Durand JO, Hugues V, Blanchard-Desce M, Maynadier M, Gallud A, Gary-Bobo M, Garcia M, Lu J, Tamanoi F, Ferris DP, Tarn D, Zink JI.

Small. 2014 May 14;10(9):1752-5. doi: 10.1002/smll.201400042. Epub 2014 Feb 20. No abstract available.

PMID:
24678053
37.

Characterization of the Raptor/4E-BP1 interaction by chemical cross-linking coupled with mass spectrometry analysis.

Coffman K, Yang B, Lu J, Tetlow AL, Pelliccio E, Lu S, Guo DC, Tang C, Dong MQ, Tamanoi F.

J Biol Chem. 2014 Feb 21;289(8):4723-34. doi: 10.1074/jbc.M113.482067. Epub 2014 Jan 8.

38.

Anticancer Effect and Molecular Targets of Saffron Carotenoids.

Bathaie SZ, Bolhassani A, Tamanoi F.

Enzymes. 2014;36:57-86. doi: 10.1016/B978-0-12-802215-3.00004-5.

PMID:
27102699
39.

Introduction.

Bathaie SZ, Tamanoi F.

Enzymes. 2014;36:1-6. doi: 10.1016/B978-0-12-802215-3.00001-X.

PMID:
27102696
40.

Preface.

Machinda Y, Lin C, Tamanoi F.

Enzymes. 2014;35:xi-xiii. doi: 10.1016/B978-0-12-801922-1.09991-7. No abstract available.

PMID:
25740722
41.

Two-photon-triggered drug delivery in cancer cells using nanoimpellers.

Croissant J, Maynadier M, Gallud A, Peindy N'dongo H, Nyalosaso JL, Derrien G, Charnay C, Durand JO, Raehm L, Serein-Spirau F, Cheminet N, Jarrosson T, Mongin O, Blanchard-Desce M, Gary-Bobo M, Garcia M, Lu J, Tamanoi F, Tarn D, Guardado-Alvarez TM, Zink JI.

Angew Chem Int Ed Engl. 2013 Dec 16;52(51):13813-7. doi: 10.1002/anie.201308647. Epub 2013 Nov 7.

42.

In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells.

Zimonjic DB, Chan LN, Tripathi V, Lu J, Kwon O, Popescu NC, Lowy DR, Tamanoi F.

BMC Cancer. 2013 Apr 22;13:198. doi: 10.1186/1471-2407-13-198.

43.

De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.

Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, Villa GR, Tanaka K, Nael A, Yang H, Dang J, Vinters HV, Yong WH, Flagg M, Tamanoi F, Sasayama T, James CD, Kornblum HI, Cloughesy TF, Cavenee WK, Bensinger SJ, Mischel PS.

Cancer Discov. 2013 May;3(5):534-47. doi: 10.1158/2159-8290.CD-12-0502. Epub 2013 Mar 26.

44.

Inhibitors of the Ras superfamily of small G-proteins. Preface.

Tamanoi F, Der CJ.

Enzymes. 2013;34 Pt. B:ix. doi: 10.1016/B978-0-12-420146-0.09985-6. Epub 2013 Nov 7. No abstract available.

PMID:
25034107
45.

Recent progress in developing small molecule inhibitors designed to interfere with ras membrane association: toward inhibiting K-Ras and N-Ras functions.

Tamanoi F, Lu J.

Enzymes. 2013;34 Pt. B:181-200. doi: 10.1016/B978-0-12-420146-0.00008-1. Epub 2013 Nov 7. Review.

PMID:
25034105
46.

Preface.

Tamanoi F.

Enzymes. 2013;33 Pt A:ix. doi: 10.1016/B978-0-12-416749-0.10000-4. Epub 2013 Aug 8. No abstract available.

PMID:
25033810
47.

A two-hybrid approach to identify inhibitors of the RAS-RAF interaction.

Khazak V, Eyrisch S, Kato J, Tamanoi F, Golemis EA.

Enzymes. 2013;33 Pt A:213-48. doi: 10.1016/B978-0-12-416749-0.00010-5. Epub 2013 Aug 8. Review.

PMID:
25033807
48.

The Ras superfamily G-proteins.

Tetlow AL, Tamanoi F.

Enzymes. 2013;33 Pt A:1-14. doi: 10.1016/B978-0-12-416749-0.00001-4. Epub 2013 Aug 8. Review.

PMID:
25033798
49.

Involvement of lysosomal exocytosis in the excretion of mesoporous silica nanoparticles and enhancement of the drug delivery effect by exocytosis inhibition.

Yanes RE, Tarn D, Hwang AA, Ferris DP, Sherman SP, Thomas CR, Lu J, Pyle AD, Zink JI, Tamanoi F.

Small. 2013 Mar 11;9(5):697-704. doi: 10.1002/smll.201201811. Epub 2012 Nov 14.

50.

Psk1, an AGC kinase family member in fission yeast, is directly phosphorylated and controlled by TORC1 and functions as S6 kinase.

Nakashima A, Otsubo Y, Yamashita A, Sato T, Yamamoto M, Tamanoi F.

J Cell Sci. 2012 Dec 1;125(Pt 23):5840-9. doi: 10.1242/jcs.111146. Epub 2012 Sep 12.

Supplemental Content

Loading ...
Support Center